TY - JOUR
T1 - Prognostic Impact of Peritumoral IL-17-Positive Cells and IL-17 Axis in Patients with Intrahepatic Cholangiocarcinoma
AU - Asukai, Kei
AU - Kawamoto, Koichi
AU - Eguchi, Hidetoshi
AU - Konno, Masamitsu
AU - Nishida, Naohiro
AU - Koseki, Jun
AU - Noguchi, Kozo
AU - Hasegawa, Shinichiro
AU - Ogawa, Hisataka
AU - Yamada, Daisaku
AU - Tomimaru, Yoshito
AU - Tomokuni, Akira
AU - Asaoka, Tadafumi
AU - Noda, Takehiro
AU - Wada, Hiroshi
AU - Gotoh, Kunihito
AU - Marubashi, Shigeru
AU - Nagano, Hiroaki
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Ishii, Hideshi
PY - 2015/12/1
Y1 - 2015/12/1
N2 - Background: Development of cancer has been linked to inflammatory cytokines such as interleukin (IL)-6 and IL-17. In this study, we assessed the expression of these cytokines in intrahepatic cholangiocarcinoma (ICC) and determined their correlation to the survival probability. Methods: A total of 72 consecutive patients who underwent curative resection of ICC at Osaka University Hospital from March 1998 to November 2014 were enrolled. Immunohistochemical analysis was performed for IL-17 and its receptor A (IL-17RA), as well as IL-6. Enzyme-linked immunosorbent assay (ELISA) was performed for preoperative plasma levels of IL-6 and IL-17 in 32 patients with ICC. Results: Immunohistochemical analysis showed that the IL-6high (n = 34) and IL-17RAhigh (n = 29) groups had significantly worse disease-free survival (DFS) than IL-6low (n = 38) and IL-17RAlow (n = 43) groups, respectively. Although IL-17+ cells were abundant in the intratumoral area, patients with high peritumoral, but not intratumoral, IL-17+ cells (n = 28) corresponded with a significantly lower overall survival (OS) and DFS (OS, p = 0.023; DFS, p = 0.026) than those with low group. Moreover, multivariate Cox proportional hazards analysis revealed that IL-6, peritumoral IL-17+, and IL-17RA are independent prognostic factors for DFS (p = 0.023, p = 0.0088, p = 0.039, respectively). In addition, high preoperative plasma levels of IL-6 in patients with ICC corresponded with significantly lower DFS (p = 0.002). Conclusions: Our data suggested that IL-6, peritumoral IL-17+ cells, and IL-17RA expression are postoperative useful markers for predicting recurrence in patients with ICC.
AB - Background: Development of cancer has been linked to inflammatory cytokines such as interleukin (IL)-6 and IL-17. In this study, we assessed the expression of these cytokines in intrahepatic cholangiocarcinoma (ICC) and determined their correlation to the survival probability. Methods: A total of 72 consecutive patients who underwent curative resection of ICC at Osaka University Hospital from March 1998 to November 2014 were enrolled. Immunohistochemical analysis was performed for IL-17 and its receptor A (IL-17RA), as well as IL-6. Enzyme-linked immunosorbent assay (ELISA) was performed for preoperative plasma levels of IL-6 and IL-17 in 32 patients with ICC. Results: Immunohistochemical analysis showed that the IL-6high (n = 34) and IL-17RAhigh (n = 29) groups had significantly worse disease-free survival (DFS) than IL-6low (n = 38) and IL-17RAlow (n = 43) groups, respectively. Although IL-17+ cells were abundant in the intratumoral area, patients with high peritumoral, but not intratumoral, IL-17+ cells (n = 28) corresponded with a significantly lower overall survival (OS) and DFS (OS, p = 0.023; DFS, p = 0.026) than those with low group. Moreover, multivariate Cox proportional hazards analysis revealed that IL-6, peritumoral IL-17+, and IL-17RA are independent prognostic factors for DFS (p = 0.023, p = 0.0088, p = 0.039, respectively). In addition, high preoperative plasma levels of IL-6 in patients with ICC corresponded with significantly lower DFS (p = 0.002). Conclusions: Our data suggested that IL-6, peritumoral IL-17+ cells, and IL-17RA expression are postoperative useful markers for predicting recurrence in patients with ICC.
UR - http://www.scopus.com/inward/record.url?scp=84952874365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952874365&partnerID=8YFLogxK
U2 - 10.1245/s10434-015-4782-y
DO - 10.1245/s10434-015-4782-y
M3 - Article
C2 - 26228109
AN - SCOPUS:84952874365
VL - 22
SP - 1524
EP - 1531
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
SN - 1068-9265
ER -